Form D · Biotechnology

4D Molecular Therapeutics Inc

Emeryville, CA · CIK 0001650648

Offering snapshot reported Sep 11, 2018 · SEC filing

Reported sold
$90M
Offering amount: $90M
Investors reported
31
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Aug 27, 2018
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Sep 11, 2018Initial$89,999,874No comparison31SEC filing
Oct 19, 2015Initial$11,594,002No comparison2SEC filing
Aug 13, 2015Initial$6,999,995No comparison1SEC filing

Offering details

Securities
Equity, Security to be acquired
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-321085

Sales compensation recipients

Scroll to see all columns →

RecipientCRDAssociated broker-dealer
N/ANone

Source: Form D, filed Sep 11, 2018. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Peter Francis, M.D. Executive
Hoyoung Huh, M.D., Ph.D. Director
Theresa Janke Executive
Leisa Johnson, Ph.D. Executive
David Kirn Director, Executive
David Kirn, M.D. Director, Executive
Margi Mc Laughlin Director
Margi Mc Loughlin Director
David Schaffer Director
David Schaffer, Ph.D., Director, Executive
Sharon Tetlow Director
Charles Theuer, Ph.D. Director
Tony Yao Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
5980 Horton Street Suite 460
Emeryville, CA, 94608